vosaroxin vosaroxin vosaroxin (ag-7352, spc-595, sns 595, voreloxin) is a topoisomerase ii inhibitor causing site-selective dna damage. it is under phase iii clinical trial investigation for acute myelogenous leukemia (aml) and ovarian cancer sponsored by sunesis. vosaroxin names preferred iupac name 7--4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid other names voreloxin identifiers cas number 175414-77-4 y 3d model (jsmol) interactive image chemspider 8128494 pubchem cid 9952884 unii k6a90iiz19 y comptox dashboard (epa) dtxsid50938662 inchi inchi=1s/c18h19n5o4s/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19h,8-9h2,1-2h3,(h,25,26)/t12-,13-/m0/s1key: xzafzxjxzhrnaq-stqmwfeesa-ninchi=1/c18h19n5o4s/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19h,8-9h2,1-2h3,(h,25,26)/t12-,13-/m0/s1key: xzafzxjxzhrnaq-stqmwfeebt smiles cn1cn(c1oc)c2=nc3=c(c=c2)c(=o)c(=cn3c4=nc=cs4)c(=o)o properties chemical formula c18h19n5o4s molar mass 401.44 g·mol−1 density 1.5±0.1 g/cm3 pharmacology atc code l01xx53 (who) except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references mechanism of action vosaroxin is a naphthyridine analog of the anticancer quinolone derivatives (aqds), a class of compounds that has not been used previously for the treatment of cancer. topoisomerase ii enzymes are essential for the survival of eukaryotic cells. vosaroxin hinders the reunion of topoisomerase ii-induced double-strand breaks at selective sites in dna, resulting in g2 arrest and cell death by apoptosis.